ArticleCancer medicine2021

Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.

Shinkichi Takamori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.